NCT06383052 - A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 26, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

177Lu-NYM032 injection

Radionuclide 177Lu will be used as a therapeutic nuclide for this study. The precursor of NYM032 will be labeled with 177Lu to form the chelation product, 177Lu-NYM032 injection which will be used in this study as a intravenous injection dose of 177Lu-NYM032. The radiation dose is chosen within the range of 50-200 mCi for an individual patient at every dose.

Trial Locations (1)

214000

Affliated Hospital of Jiangnan University, Wuxi

All Listed Sponsors

lead

Norroy Bioscience Co., LTD

INDUSTRY